Leonardo Tondo

Prof. Dr. Leonardo Tondo


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2019 in International Journal of Bipolar Disorders
Verified
Journal Article
Open access
PDF file
F(for the International Group for Studies of Lithium (IGSLi)
for the International Group for Studies of Lithium (IGSLi)
LTLeonardo Tondo
Leonardo Tondo
MAMartin Alda
Martin Alda
MBMichael Bauer
Michael Bauer
VBVeerle Bergink
Veerle Bergink
RBRoss J. Baldessarini
Ross J. Baldessarini
Lithium has been used clinically for 70 years, mainly to treat bipolar disorder. Competing treatments and exaggerated impressions about complexity and risks of lithium treatment have led to its declining use in some countries, encouraging this update about its safe clinical use. We conducted a nonsystematic review of recent research reports and developed consensus among international experts on the use of lithium to treat major mood disorders, aiming for a simple but authoritative guide for patients and prescribers. We summarized recommendations concerning safe clinical use of lithium salts to treat major mood disorders, including indications, dosing, clinical monitoring, adverse effects and use in specific circumstances including during pregnancy and for the elderly. Lithium continues as the standard and most extensively evaluated treatment for bipolar disorder, especially for long-term prophylaxis.

28 February 2017 in Current Neuropharmacology
Verified
Journal Article
Open access
LTLeonardo Tondo
Leonardo Tondo
GVGustavo Vazquez
Gustavo Vazquez
RBRoss Baldessarini
Ross Baldessarini
Background: Episode duration, recurrence rates, and time spent in manic and depressive phases of bipolar disorder (BD) is not well defined for subtypes of the disorder. Methods: We reviewed the course, timing, and duration of episodes of mania and depression among 1130 clinically treated DSM-IV-TR BD patients of various types, and compared duration and rates as well as total proportion of time in depressive versus manic episodes during 16.7 average years at risk. Results: As expected, episodes of depressions were much longer than manias, but episode-duration did not differ among BD diagnostic types: I, II, with mainly mixed-episodes (BD-Mx), or with psychotic features (BD-P). Recurrence rates (episodes/year) and proportion of time in depression and their ratios to mania were highest in BD-II and BD-Mx subjects, with more manias/year in psychotic and BD-I subjects. In most BD-subtypes, except with psychotic features, there was more time in depressive than manic morbidity, owing mainly to longer depressive than manic episodes. The proportion of time in depression was highest among those who followed a predominant DMI course, whereas total time in mania was greatest in BD with psychotic features and BD-I. and with an MDI course. Conclusions: Subtypes of BD patients differed little in episode-duration, which was consistently much longer for depression. The findings underscore the limited control of bipolar depression with available treatments.

11 November 2015 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Closed access
PDF file
LTLeonardo Tondo
Leonardo Tondo
MPM. Pompili
M. Pompili
AFAlberto Forte
Alberto Forte
RBR. J. Baldessarini
R. J. Baldessarini

1 August 2017 in International Journal of Bipolar Disorders
Verified
Journal Article
Open access
PDF file
LTLeonardo Tondo
Leonardo Tondo
MAMaria Abramowicz
Maria Abramowicz
MAMartin Alda
Martin Alda
MBMichael Bauer
Michael Bauer
ABAlberto Bocchetta
Alberto Bocchetta
RBRoss Baldessarini
Ross Baldessarini
Concerns about potential adverse effects of long-term exposure to lithium as a mood-stabilizing treatment notably include altered renal function. However, the incidence of severe renal dysfunction; rate of decline over time; effects of lithium dose, serum concentration, and duration of treatment; relative effects of lithium exposure vs. aging; and contributions of sex and other factors all remain unclear. Accordingly, we acquired data from 12 collaborating international sites and 312 bipolar disorder patients (6142 person-years, 2669 assays) treated with lithium carbonate for 8–48 (mean 18) years and aged 20–89 (mean 56) years. We evaluated changes of estimated glomerular filtration rate (eGFR) as well as serum creatinine, urea–nitrogen, and glucose concentrations, white blood cell count, and body-mass index, and tested associations of eGFR with selected factors, using standard bivariate contrasts and regression modeling. Overall, 29.5% of subjects experienced at least one low value of eGFR ( 55; risk of ≥2 low values was 18.1%; none experienced end-stage renal failure. eGFR declined by 0.71%/year of age and 0.92%/year of treatment, both by 19% more among women than men. Mean serum creatinine increased from 0.87 to 1.17 mg/dL, BUN from 23.7 to 33.1 mg/dL, glucose from 88 to 122 mg/dL, and BMI from 25.9 to 26.6 kg/m2. By multivariate regression, risk factors for declining eGFR ranked: longer lithium treatment, lower lithium dose, higher serum lithium concentration, older age, and medical comorbidity. Later low eGFR was also predicted by lower initial eGFR, and starting lithium at age ≥ 40 years. Control data for age-matched subjects not exposed to lithium were lacking. Long-term lithium treatment was associated with gradual decline of renal functioning (eGFR) by about 30% more than that was associated with aging alone. Risk of subnormal eGFR was from 18.1% (≥2 low values) to 29.5% (≥1 low value), requiring about 30 years of exposure. Additional risk factors for low eGFR were higher serum lithium level, longer lithium treatment, lower initial eGFR, and medical comorbidity, as well as older age.

1 June 2001 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
LTLeonardo Tondo
Leonardo Tondo
RBRoss J. Baldessarini
Ross J. Baldessarini
GFGianfranco Floris
Gianfranco Floris
Background: The effectiveness of lithium is being questioned increasingly and requires clarification.Aims: To assess the effectiveness of lithium treatment in depression and mania, syndromal types I and II, with predominantly mixed or psychotic episodes or rapid cycling, during treatment resumed following discontinuation, and across three decades.Method: The longitudinal course of 360 patients with bipolar disorder compliant with lithium treatment for at least 1 year and without comorbidity for substance use disorder was reviewed.Results: Risk of single-episode recurrences, a common index of treatment failure, was similar to that in other reports. Both episode frequency and ‘time ill’ improved more in type II than type I cases. Reduced morbidity during treatment was similar in patients with mixed or psychotic episodes, or rapid cycling, and in less complex cases. Retreatment yielded minor decrements in response, and there was no tendency for lesser responses in more recent years.Conclusions: Based on overall affective morbidity, long-term lithium treatment in compliant patients without comorbid substance use disorder, though imperfect, remains effective, even in subgroups of supposedly poor prognosis.

9 October 2020 in Bipolar Disorders
Verified
Journal Article
Closed access
PDF file
LTLeonardo Tondo
Leonardo Tondo
GVGustavo H. Vázquez
Gustavo H. Vázquez
RBRoss Baldessarini
Ross Baldessarini